Cinryze (C1 inhibitor (human))
- Region
- 🇪🇺 EU
- Active substance
- C1 inhibitor (human)
- Company
- Takeda Manufacturing Austria AG
- Status
- Authorised
- Therapeutic area
- Angioedemas, Hereditary
- CHMP opinion
- Thu 17 Mar 2011
- EU approval
- Wed 15 Jun 2011
- Application
- EMEA/H/C/001207
- ATC
- B06AC01
- Official record
- www.ema.europa.eu
Indication
Treatment and pre-procedure prevention of angioedema attacks in adults, adolescents and children (2 years old and above) with hereditary angioedema (HAE). Routine prevention of angioedema attacks in adults, adolescents and children (6 years old and above) with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment.
Regulatory milestones
No milestones recorded in the last year.
Follow Cinryze
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.